Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
Title | Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis. |
Publication Type | Journal Article |
Year of Publication | 2020 |
Authors | Mantsiou, C., Karagiannis T., Kakotrichi P., Malandris K., Avgerinos I., Liakos A., Tsapas A., & Bekiari E. |
Journal | Diabetes Obes Metab |
Volume | 22 |
Issue | 10 |
Pagination | 1857-1868 |
Date Published | 2020 10 |
ISSN | 1463-1326 |
Keywords | Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor, Glucose, Humans, Hypoglycemic Agents, Sodium, Sodium-Glucose Transporter 2 Inhibitors, Symporters |
Abstract | AIM: To assess the efficacy and safety of combination therapy with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and a sodium-glucose co-transporter-2 inhibitor (SGLT2i) in patients with type 2 diabetes. |
DOI | 10.1111/dom.14108 |
Alternate Journal | Diabetes Obes Metab |
PubMed ID | 32476254 |